SAN FRANCISCO, Aug. 04, 2025 - Olema Pharmaceuticals, Inc. ("Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company, has announced the issuance of stock options to four new employees, allowing them to purchase a total of 130,000 shares of the company's common stock. Effective as of August 1, 2025, these stock options were sanctioned by Olema's Board of Directors' Compensation Committee as part of the 2022 Inducement Plan. The options, which have a 10-year term and an exercise price of $5.33 per share, vest over four years. This includes 25 percent vesting on the first anniversary of the commencement date, followed by monthly vesting over the next three years, contingent on ongoing employment with Olema. This move aligns with Nasdaq Listing Rule 5635(c)(4).